6185.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 10:32):

Stats
Dzisiejszy wolumen	701 000
Średni wolumen	1.11M
Kapitalizacja rynkowa	7.07B
EPS	HKD-0.580 ( 2023-10-30 )
Last Dividend	HKD0.937 ( 2022-07-13 )
Next Dividend	HKD0 ( N/A )
P/E	-3.35
ATR14	HKD0.0240 (0.11%)

Wolumen Korelacja

Długi: 0.36 (neutral)

Krótki: 0.00 (neutral)

Signal:(57.265) Neutral

Cansino Biologics Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cansino Biologics Inc Korelacja - Waluta/Towar

0.70
( moderate )

0.36
( neutral )

0.00
( neutral )

-0.47
( neutral )

-0.63
( weak negative )

-0.79
( moderate negative )

Cansino Biologics Inc Finanse

Annual	2023
Przychody:	HKD345.18M
Zysk brutto:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2023
Przychody:	HKD345.18M
Zysk brutto:	HKD-876.02M (-253.78 %)
EPS:	HKD-6.01

FY	2022
Przychody:	HKD1.03B
Zysk brutto:	HKD-186.61M (-18.10 %)
EPS:	HKD-3.91

FY	2021
Przychody:	HKD4.30B
Zysk brutto:	HKD3.00B (69.85 %)
EPS:	HKD7.74

Financial Reports:

No articles found.

Cansino Biologics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.937 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Cansino Biologics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.937	2022-07-13
Last Dividend	HKD0.937	2022-07-13
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	HKD0.937	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-03)

HKD0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6178.HK	Ex Dividend Junior	2023-07-12	Annually	0.00%
1861.HK	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
0883.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
0026.HK	Ex Dividend Junior	2023-10-03	Semi-Annually	0.00%
2688.HK	Ex Dividend Junior	2023-11-02	Annually	0.00%
1433.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%
0520.HK	Ex Dividend Junior	2023-10-05	Semi-Annually	0.00%
6889.HK	Ex Dividend Junior	2023-06-02	Semi-Annually	0.00%
1980.HK	No Dividend Player	2023-09-13	Sporadic	0.00%
1044.HK	Ex Dividend Knight	2023-09-18	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-4.24	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.159	1.200	-5.30	-6.36	[0 - 0.3]
returnOnEquityTTM	-0.252	1.500	-3.91	-5.86	[0.1 - 1]
payoutRatioTTM	-0.0725	-1.000	-0.725	0.725	[0 - 1]
currentRatioTTM	1.999	0.800	5.01	4.00	[1 - 3]
quickRatioTTM	1.835	0.800	3.91	3.13	[0.8 - 2.5]
cashRatioTTM	0.790	1.500	6.72	10.00	[0.2 - 2]
debtRatioTTM	0.290	-1.500	5.17	-7.76	[0 - 0.6]
interestCoverageTTM	-37.09	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
freeCashFlowPerShareTTM	-6.10	2.00	-3.05	-6.10	[0 - 20]
debtEquityRatioTTM	0.512	-1.500	7.95	-10.00	[0 - 2.5]
grossProfitMarginTTM	-1.411	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-3.70	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.330	1.000	-2.95	-2.95	[0.2 - 2]
assetTurnoverTTM	0.0376	0.800	-3.08	-2.47	[0.5 - 2]
Total Score				-3.45

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.28	1.000	-0.433	0	[1 - 100]
returnOnEquityTTM	-0.252	2.50	-2.51	-5.86	[0.1 - 1.5]
freeCashFlowPerShareTTM	-6.10	2.00	-2.03	-6.10	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-3.62	2.00	-1.207	-2.41	[0 - 30]
payoutRatioTTM	-0.0725	1.500	-0.725	0.725	[0 - 1]
pegRatioTTM	0.116	1.500	-2.56	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.55	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.81

Cansino Biologics Inc

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.